Tuesday, 4 September 2018

Microbial Therapy for Ulcerative Colitis


Microbiotica, a leading player in microbiome-based therapeutics, today announced that it has entered into an agreement with University of Adelaide as part of its programme to develop a defined bacterial product for ulcerative colitis (UC). Financial details have not been disclosed.

Microbiotica is collaborating with Dr Sam Costello, Adelaide Medical School, University of Adelaide and Department of Gastroenterology at the Queen Elizabeth Hospital, to develop a new therapeutic to treat UC. Dr Costello led a faecal microbiota transplantation (FMT) study the results of which demonstrate the ability to induce remission in UC, without significant side-effects. This data is compelling evidence for a novel therapeutic approach based on resetting gut microbiota.

Under the agreement, Microbiotica will analyse clinical samples from the Adelaide FMT study to identify the specific bacteria which successfully treated the condition. Microbiotica has developed the leading platform for culture-based precision metagenomics, enabling large-scale strain-level characterisation of microbiome profiles linked to patient phenotype.

Further details: Microbiome Times

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology

Special offers